Xiaomin Fu

1.1k total citations
40 papers, 738 citations indexed

About

Xiaomin Fu is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Xiaomin Fu has authored 40 papers receiving a total of 738 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 15 papers in Oncology and 7 papers in Immunology. Recurrent topics in Xiaomin Fu's work include Cancer Immunotherapy and Biomarkers (8 papers), Advanced biosensing and bioanalysis techniques (5 papers) and Bone Metabolism and Diseases (5 papers). Xiaomin Fu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Advanced biosensing and bioanalysis techniques (5 papers) and Bone Metabolism and Diseases (5 papers). Xiaomin Fu collaborates with scholars based in China and United States. Xiaomin Fu's co-authors include Ruo Yuan, Xingrong Tan, Shihong Chen, Dianshan Ke, Shihong Chen, Yong Zhang, Ying Xue, Na Wang, Jianming Hou and Lingdi Zhao and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Biomaterials.

In The Last Decade

Xiaomin Fu

39 papers receiving 726 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaomin Fu China 16 379 153 152 147 107 40 738
Jae Min Jung South Korea 21 380 1.0× 239 1.6× 147 1.0× 62 0.4× 116 1.1× 34 950
Sheng-Chun Dang China 14 157 0.4× 124 0.8× 101 0.7× 85 0.6× 77 0.7× 41 572
Rong Zheng China 14 265 0.7× 56 0.4× 110 0.7× 107 0.7× 316 3.0× 64 839
Xinyu Jiang China 15 193 0.5× 93 0.6× 150 1.0× 57 0.4× 74 0.7× 32 566
Fangqin Xue China 15 370 1.0× 168 1.1× 286 1.9× 78 0.5× 80 0.7× 39 724
Fuqiang Shao China 16 142 0.4× 66 0.4× 112 0.7× 249 1.7× 153 1.4× 76 806
Tongyi Huang China 17 311 0.8× 126 0.8× 263 1.7× 208 1.4× 107 1.0× 37 1.2k
Xinyu Wan China 16 253 0.7× 70 0.5× 103 0.7× 91 0.6× 79 0.7× 53 556
Baosan Han China 17 317 0.8× 89 0.6× 208 1.4× 105 0.7× 59 0.6× 31 829

Countries citing papers authored by Xiaomin Fu

Since Specialization
Citations

This map shows the geographic impact of Xiaomin Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaomin Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaomin Fu more than expected).

Fields of papers citing papers by Xiaomin Fu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaomin Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaomin Fu. The network helps show where Xiaomin Fu may publish in the future.

Co-authorship network of co-authors of Xiaomin Fu

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaomin Fu. A scholar is included among the top collaborators of Xiaomin Fu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaomin Fu. Xiaomin Fu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fu, Xiaomin, et al.. (2024). Combination therapy using low‐dose anlotinib and immune checkpoint inhibitors for extensive‐stage small cell lung cancer. SHILAP Revista de lepidopterología. 3(6). e155–e155. 2 indexed citations
2.
3.
Liu, Hongzhou, Linlin Wang, Xiaojing Li, et al.. (2024). The causal relationship between 5 serum lipid parameters and diabetic nephropathy: a Mendelian randomization study. Frontiers in Endocrinology. 15. 1358358–1358358. 3 indexed citations
4.
Liu, Li, Shengxiang Fu, Wencheng Zhu, et al.. (2023). Glucosylation endows nanoparticles with TLR4 agonist capability to trigger macrophage polarization and augment antitumor immunity. Biomaterials. 304. 122424–122424. 14 indexed citations
5.
Fu, Qiang, Lingdi Zhao, Xiaomin Fu, et al.. (2022). Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma. The Oncologist. 27(6). e463–e470. 9 indexed citations
6.
7.
Peng, Ling, Bicheng Zhang, Brian G. Till, et al.. (2022). Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced Malignancies. Frontiers in Immunology. 13. 882172–882172. 4 indexed citations
8.
Shang, Yiman, Yong Zhang, Xiaomin Fu, et al.. (2022). Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer. Frontiers in Oncology. 12. 852885–852885. 5 indexed citations
9.
Yang, Jing, Xiangyun Wang, Jingli Lü, et al.. (2021). Genomic Profiling of Circulating Tumor DNA from Patients with Extensive-Stage Small Cell Lung Cancer Identifies Potentially Actionable Alterations. Journal of Cancer. 12(17). 5099–5105. 11 indexed citations
10.
Zhao, Lingdi, Wenqun Xing, Yonghao Yang, et al.. (2021). The sequence of chemotherapy and anti-PD-1 antibody influence the efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell cancer: A phase II study.. Journal of Clinical Oncology. 39(15_suppl). 4051–4051. 13 indexed citations
11.
Zhang, Yong, Fang Zhang, Lingdi Zhao, et al.. (2021). Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature. BMC Gastroenterology. 21(1). 399–399. 3 indexed citations
12.
Xing, Wenqun, Lingdi Zhao, Xiaomin Fu, et al.. (2020). A phase II, single-centre trial of neoadjuvant toripalimab plus chemotherapy in locally advanced esophageal squamous cell carcinoma. Journal of Thoracic Disease. 12(11). 6861–6867. 18 indexed citations
13.
Ke, Dianshan, et al.. (2020). Puerarin inhibits the migration of osteoclast precursors and osteoclastogenesis by inhibiting MCP-1 production. Bioscience Biotechnology and Biochemistry. 84(7). 1455–1459. 6 indexed citations
14.
Ke, Dianshan, et al.. (2019). Autophagy mediated by JNK1 resists apoptosis through TRAF3 degradation in osteoclastogenesis. Biochimie. 167. 217–227. 18 indexed citations
15.
Fu, Xiaomin, et al.. (2019). Elevated platelet-to-lymphocyte corresponds with poor outcome in patients with advanced cancer receiving anti-PD-1 therapy. International Immunopharmacology. 74. 105707–105707. 14 indexed citations
16.
Fu, Xiaomin, et al.. (2018). IL-17A modulates osteoclast precursors' apoptosis through autophagy-TRAF3 signaling during osteoclastogenesis. Biochemical and Biophysical Research Communications. 508(4). 1088–1092. 32 indexed citations
17.
Ke, Dianshan, Xiaomin Fu, Ying Xue, et al.. (2018). IL-17A regulates the autophagic activity of osteoclast precursors through RANKL-JNK1 signaling during osteoclastogenesis in vitro. Biochemical and Biophysical Research Communications. 497(3). 890–896. 53 indexed citations
18.
Zhang, Yong, et al.. (2018). Platelet-to-lymphocyte ratio in peripheral blood: A novel independent prognostic factor in patients with melanoma. International Immunopharmacology. 56. 143–147. 17 indexed citations
19.
20.
Fu, Xiaomin, Xingrong Tan, Ruo Yuan, & Shihong Chen. (2016). A dual-potential electrochemiluminescence ratiometric sensor for sensitive detection of dopamine based on graphene-CdTe quantum dots and self-enhanced Ru(II) complex. Biosensors and Bioelectronics. 90. 61–68. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jae Min Jung Breakdown of academic impact, for papers by Sheng-Chun Dang Breakdown of academic impact, for papers by Rong Zheng Breakdown of academic impact, for papers by Xinyu Jiang Breakdown of academic impact, for papers by Fangqin Xue Breakdown of academic impact, for papers by Fuqiang Shao Breakdown of academic impact, for papers by Tongyi Huang Breakdown of academic impact, for papers by Xinyu Wan Breakdown of academic impact, for papers by Baosan Han
Rankless by CCL
2026